Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Dec;136(12):1915-20.
doi: 10.1007/s00432-010-0850-7. Epub 2010 Mar 6.

Role of anti-Her-2 therapy in bladder carcinoma

Alvaro Pinto Marín  1 , Enrique Espinosa Arranz, Andrés Redondo Sánchez, Pilar Zamora Auñón, Manuel González Barón
Affiliations
Review

Role of anti-Her-2 therapy in bladder carcinoma

Alvaro Pinto Marín et al. J Cancer Res Clin Oncol. 2010 Dec.

Abstract

Bladder cancer, in its advanced stage, has very few therapeutic strategies with proven efficacy. Platinum-combination chemotherapy can be considered a standard for first-line therapy, but after progression there is no standard therapy, and the prognosis is very poor. The development of targeted therapies in the last few years has significantly changed the prognosis of a wide variety of tumors. In bladder cancer, there is no targeted therapy currently approved for its use in advanced disease. There is evidence that Her-2 amplification and/or overexpression is seen in bladder cancer, and may influence prognosis. Anti-Her-2 drugs, such as trastuzumab or lapatinib, are under investigation in urothelial neoplasms, but there is no phase III trial that has evaluated their use in bladder cancer. We review the published evidence about Her-2 determination, its influence on bladder carcinoma prognosis, the clinical development of anti-Her-2-targeted therapies, and the possible future research directions involving this pathway in bladder cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Summarized view of the EGFR-HER2 pathway
See this image and copyright information in PMC

References

    1. Bellmunt J, Hussain M, Dinney CP (2003) Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 46:S85–S104 - PubMed
    1. Caner V, Turk NS, Duzcan F et al (2008) No strong association between Her-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res 14:261–266 - PubMed
    1. Chakravarti A, Winter K, Wu CL et al (2005) Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 62(2):309–317 - PubMed
    1. Chow NH, Chan SH, Tzai TS et al (2001) Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7:1957–1962 - PubMed
    1. Coogan CL, Estrada CR, Kapur S, Bloom KJ (2004) Her-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 63:786–790 - PubMed

MeSH terms